These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 36205223)

  • 1. Natural Product-Inspired Targeted Protein Degraders: Advances and Perspectives.
    Li J; Cai Z; Li XW; Zhuang C
    J Med Chem; 2022 Oct; 65(20):13533-13560. PubMed ID: 36205223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of natural product-based targeted protein degraders as anticancer agents.
    Chen C; Feng Y; Zhou C; Liu Z; Tang Z; Zhang Y; Li T; Gu C; Chen J
    Bioorg Chem; 2024 Sep; 153():107772. PubMed ID: 39243739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteolysis-targeting drug delivery system (ProDDS): integrating targeted protein degradation concepts into formulation design.
    Chen Y; Liu F; Pal S; Hu Q
    Chem Soc Rev; 2024 Sep; 53(19):9582-9608. PubMed ID: 39171633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PROTAC derivatization of natural products for target identification and drug discovery: Design of evodiamine-based PROTACs as novel REXO4 degraders.
    Chen S; Bi K; Liang H; Wu Z; Huang M; Chen X; Dong G; Sheng C
    J Adv Res; 2024 Sep; 63():219-230. PubMed ID: 37913903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breaking Bad Proteins-Discovery Approaches and the Road to Clinic for Degraders.
    Bouvier C; Lawrence R; Cavallo F; Xolalpa W; Jordan A; Hjerpe R; Rodriguez MS
    Cells; 2024 Mar; 13(7):. PubMed ID: 38607017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the STAT3 pathway with STAT3 degraders.
    Wang Z; Liao X; He H; Guo X; Chen J
    Trends Pharmacol Sci; 2024 Sep; 45(9):811-823. PubMed ID: 39117533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted protein degradation in drug development: Recent advances and future challenges.
    Song J; Hu M; Zhou J; Xie S; Li T; Li Y
    Eur J Med Chem; 2023 Dec; 261():115839. PubMed ID: 37778240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PROTAC targeted protein degraders: the past is prologue.
    Békés M; Langley DR; Crews CM
    Nat Rev Drug Discov; 2022 Mar; 21(3):181-200. PubMed ID: 35042991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond canonical PROTAC: biological targeted protein degradation (bioTPD).
    Wang H; Zhou R; Xu F; Yang K; Zheng L; Zhao P; Shi G; Dai L; Xu C; Yu L; Li Z; Wang J; Wang J
    Biomater Res; 2023 Jul; 27(1):72. PubMed ID: 37480049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress of small molecules for targeted protein degradation: PROTACs and other technologies.
    Zhao HY; Xin M; Zhang SQ
    Drug Dev Res; 2023 Apr; 84(2):337-394. PubMed ID: 36606428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulfur-containing marine natural products as leads for drug discovery and development.
    Guo FW; Zhang Q; Gu YC; Shao CL
    Curr Opin Chem Biol; 2023 Aug; 75():102330. PubMed ID: 37257309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROTACs technology for targeting non-oncoproteins: Advances and perspectives.
    Wang C; Zhang Y; Xing D; Zhang R
    Bioorg Chem; 2021 Sep; 114():105109. PubMed ID: 34175722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation.
    Bond MJ; Crews CM
    RSC Chem Biol; 2021 Mar; 2(3):725-742. PubMed ID: 34212149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rise and rise of protein degradation: Opportunities and challenges ahead.
    Hughes SJ; Testa A; Thompson N; Churcher I
    Drug Discov Today; 2021 Dec; 26(12):2889-2897. PubMed ID: 34419629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular glue degraders: exciting opportunities for novel drug discovery.
    Lemaitre T; Cornu M; Schwalen F; Since M; Kieffer C; Voisin-Chiret AS
    Expert Opin Drug Discov; 2024 Apr; 19(4):433-449. PubMed ID: 38240114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery.
    Xi JY; Zhang RY; Chen K; Yao L; Li MQ; Jiang R; Li XY; Fan L
    Bioorg Chem; 2022 Aug; 125():105848. PubMed ID: 35533582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in developing degraders & inhibitors of lysine methyltransferases.
    Velez J; Kaniskan HÜ; Jin J
    Curr Opin Chem Biol; 2023 Oct; 76():102356. PubMed ID: 37379717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rise of degrader drugs.
    Teng M; Gray NS
    Cell Chem Biol; 2023 Aug; 30(8):864-878. PubMed ID: 37494935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted protein degrader development for cancer: advances, challenges, and opportunities.
    Fang Y; Wang S; Han S; Zhao Y; Yu C; Liu H; Li N
    Trends Pharmacol Sci; 2023 May; 44(5):303-317. PubMed ID: 37059054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins.
    Lin J; Jin J; Shen Y; Zhang L; Gong G; Bian H; Chen H; Nagle DG; Wu Y; Zhang W; Luan X
    Theranostics; 2021; 11(17):8337-8349. PubMed ID: 34373745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.